Grufity logoGrufity logo
StocksFundsSearch Filings

Halyard Health Inc Stock Research

AVNS

23.39USD+0.41(+1.78%)Market Closed

Market Summary

USD23.39+0.41
Market Closed
1.78%

AVNS Alerts

AVNS Stock Price

AVNS RSI Chart

AVNS Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

24.47

Price/Sales (Trailing)

1.34

EV/EBITDA

8.41

Price/Free Cashflow

13.26

AVNS Price/Sales (Trailing)

AVNS Profitability

EBT Margin

7.95%

Return on Equity

3.91%

Return on Assets

2.83%

Free Cashflow Yield

7.54%

AVNS Fundamentals

AVNS Revenue

Revenue (TTM)

814.3M

Revenue Y/Y

-2.89%

Revenue Q/Q

-11.86%

AVNS Earnings

Earnings (TTM)

44.6M

Earnings Y/Y

-109.26%

Earnings Q/Q

-102.96%

Price Action

52 Week Range

19.3231.99
(Low)(High)

Last 7 days

3.8%

Last 30 days

-20.1%

Last 90 days

-18.4%

Trailing 12 Months

-16.2%

AVNS Financial Health

Current Ratio

2.69

Debt/Equity

0.19

Debt/Cashflow

0.37

AVNS Investor Care

Buy Backs (1Y)

1.40%

Diluted EPS (TTM)

0.94

Peers (Alternatives to Halyard Health)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
SYK
110.8B
19.0B
 -8.78% 16.43%
46.98
6.01
 8.73% 30.37%
MDT
108.4B
30.8B
 -9.46% -17.45%
26.61
3.52
 -3.19% -17.32%
ISRG
107.5B
6.4B
 4.05% 37.44%
81.96
16.72
 8.89% -20.19%
BDX
71.3B
18.8B
 -6.73% -3.13%
44.09
3.79
 -1.96% -15.83%
EW
49.7B
5.5B
 -6.18% -16.80%
33.38
9.03
 2.68% -3.23%
MID-CAP
SWAV
7.2T
557.2M
 -1.64% 66.40%
82.2K
16.8K
 86.42% 730.06%
PEN
11.7B
884.6M
 7.85% 115.97%
1.8K
13.2
 13.08% 200.12%
GMED
5.9B
1.1B
 -8.20% -19.98%
34.14
5.75
 11.20% 53.04%
IRTC
3.6B
430.0M
 -11.89% -12.63%
-34.73
8.45
 26.13% 15.73%
TNDM
1.7B
794.7M
 -29.15% -60.56%
-8.43
2.16
 7.73% -3556.34%
SMALL-CAP
SILK
1.2B
150.7M
 -30.80% 0.49%
-21.65
7.87
 40.31% 1.80%
AVNS
1.1B
814.3M
 -20.14% -16.22%
24.47
1.34
 6.96% 121.89%
BLFS
974.0M
163.2M
 25.14% 71.36%
-6.65
5.97
 17.84% -885.82%
CSII
839.3M
239.8M
 0.70% 0.15%
-22.16
3.5
 -4.74% -31.15%

Financials for Halyard Health

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue-0.7%814820796778761
Gross Profit-0.8%446450431411382
  S&GA Expenses0.8%345342335327317
  R&D Expenses0.3%31.0031.0031.0032.0032.00
EBITDA3.2%12311910162.00-
EBITDA Margin0.2%0.15*0.15*0.13*0.08*-
Earnings Before Taxes-11.8%58.0065.0068.0054.0029.00
EBT Margin-6.4%0.08*0.08*0.07*0.04*-
Interest Expenses22.0%12.0010.008.006.004.00
Net Income-11.7%45.0051.0045.00-5.9020.00
Net Income Margin8.7%0.06*0.06*-0.01*0.02*-
Free Cahsflow-16.8%91.0010910492.00-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-2.9%1,7351,7871,7751,7531,767
  Current Assets-9.2%454500470437439
    Cash Equivalents-25.1%96.00128117107104
  Inventory5.1%200190194169158
  Net PPE-0.2%164164163164167
  Goodwill0.3%822819824825826
Liabilities-12.0%436496512501510
  Current Liabilities-14.7%159186162151153
  Long Term Debt-0.6%248249254--
    LT Debt, Current0%6.006.006.005.00-
    LT Debt, Non Current-226----
Shareholder's Equity0.6%1,2991,2911,2641,2591,263
  Retained Earnings-0.2%-253-253-270-293-304
  Additional Paid-In Capital0.3%1,6511,6461,6421,6371,633
Accumulated Depreciation2.1%149146142--
Shares Outstanding0.3%47.0047.0046.0047.0047.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-9.5%82.0091.0010910492.00
  Share Based Compensation1.3%16.0016.0015.0014.0014.00
Cashflow From Investing86.9%-17.70-135-135-135-137
Cashflow From Financing-225.4%-71.1057.0053.0044.0051.00
  Buy Backs-40.2%27.0046.0056.0045.0031.00

Risks for AVNS

What is the probability of a big loss on AVNS?

89.2%

Probability that Halyard Health stock will be more than 20% underwater in next one year

82.3%

Probability that Halyard Health stock will be more than 30% underwater in next one year.

46.1%

Probability that Halyard Health stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AVNS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Halyard Health was unfortunately bought at previous high price.

Drawdowns

Returns for AVNS

Cumulative Returns on AVNS

-1.2%

10-Year Cumulative Returns

-3.8%

7-Year Cumulative Returns

-15.4%

5-Year Cumulative Returns

-7.6%

3-Year Cumulative Returns

What are the long-term rolling returns for AVNS?

FIve years rolling returns for Halyard Health.

Annualized Returns

Which funds bought or sold AVNS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
Front Row Advisors LLC
unchanged
-
-
2,000
 -%
2023-05-22
AMERIPRISE FINANCIAL INC
added
6.11
1,549,650
10,880,600
 -%
2023-05-22
PUTNAM INVESTMENTS LLC
reduced
-4.06
47,921
929,346
 -%
2023-05-19
CHELSEA COUNSEL CO
sold off
-100
-135
-
 -%
2023-05-18
JPMORGAN CHASE & CO
added
10.16
531,665
3,057,660
 -%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-37.65
-479,000
1,042,000
 -%
2023-05-17
Thrivent Financial for Lutherans
reduced
-1.99
170,000
2,366,000
 0.01%
2023-05-17
VIRGINIA RETIREMENT SYSTEMS ET AL
new
-
270,600
270,600
 -%
2023-05-17
Advisory Services Network, LLC
reduced
-47.54
-1,398
1,903
 -%
2023-05-17
Sunbelt Securities, Inc.
new
-
604
604
 -%

1–10 of 48

Latest Funds Activity

Are funds buying AVNS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own AVNS
No. of Funds

AVNS Alerts

Halyard Health News

Mass Device
Avanos Medical fills two new C-level posts.
Mass Device,
4 months ago
Mass Device
Halyard Health to rebrand as Avanos Medical.
Mass Device,
4 years ago
Seeking Alpha
McKesson To Acquire MSD For Medical Supply Distribution (NYSE ....
Seeking Alpha,
5 years ago
Seeking Alpha
Seeking Blackrock: Swimming With The Alpha Whale (NYSE:BLK).
Seeking Alpha,
8 years ago

Schedule 13G FIlings of Halyard Health

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
rgm capital, llc
5.71%
2,653,104
SC 13G/A
Feb 09, 2023
vanguard group inc
11.83%
5,500,000
SC 13G/A
Feb 08, 2023
paradice investment management llc
5.0%
2,343,232
SC 13G/A
Jan 26, 2023
blackrock inc.
16.3%
7,571,048
SC 13G/A
Jan 20, 2023
blackrock inc.
16.3%
7,571,048
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
0.2%
133,980
SC 13G/A
Feb 11, 2022
champlain investment partners, llc
2.44%
1,174,483
SC 13G/A
Feb 11, 2022
rgm capital, llc
6.08%
2,930,872
SC 13G
Feb 09, 2022
vanguard group inc
10.84%
5,221,786
SC 13G/A
Feb 04, 2022
wellington management group llp
2.75%
1,325,674
SC 13G/A

AVNS Fair Value

Halyard Health fair value in different scenarios

The table shows the Fair Value estimates for Halyard Health for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

21.22

-9.28%

26.07

11.46%

32.29

38.05%

54.97

135.01%

69.04

195.17%
Current Inflation

20.16

-13.81%

24.36

4.15%

29.62

26.64%

49.06

109.75%

60.98

160.71%
Very High Inflation

18.84

-19.45%

22.27

-4.79%

26.43

13.00%

42.15

80.21%

51.61

120.65%

Historical Halyard Health Fair Value Estimates

Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Halyard Health

View All Filings
Date Filed Form Type Document
May 25, 2023
SD
SD
May 09, 2023
4
Insider Trading
May 09, 2023
4
Insider Trading
May 09, 2023
4
Insider Trading
May 03, 2023
10-Q
Quarterly Report
May 03, 2023
8-K
Current Report
Mar 23, 2023
4/A
Insider Trading
Mar 23, 2023
4/A
Insider Trading
Mar 17, 2023
ARS
ARS
Mar 17, 2023
DEF 14A
DEF 14A

Latest Insider Trading transactions for AVNS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-08
Woody Joseph Fralin
sold (taxes)
-1,372,430
23.97
-57,256
chief executive officer
2023-05-08
Greiner Michael
sold (taxes)
-352,599
23.97
-14,710
svp - chief financial officer
2023-05-08
Holbrook Kerr
sold (taxes)
-42,474
23.97
-1,772
svp, chief commercial officer
2023-03-06
Greiner Michael
acquired
-
-
36,350
svp - chief financial officer
2023-03-06
Holbrook Kerr
sold (taxes)
-44,815
29.62
-1,513
svp, gm chronic care
2023-03-06
James Mojirade
acquired
-
-
20,339
svp, general counsel
2023-03-06
Sarker Arjun Ranjan
acquired
-
-
4,562
senior vp, international
2023-03-06
Woody Joseph Fralin
sold (taxes)
-246,261
29.62
-8,314
chief executive officer
2023-03-06
Haydon William David
sold (taxes)
-44,815
29.62
-1,513
svp, gm pain franchise
2023-03-06
Varshney Sudhakar
acquired
-
-
12,463
svp, global supply chain

1–10 of 50

About Halyard Health

Joseph F. Woody
www.halyardhealth.com
4560
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

AVNS Income Statement

2023-03-31
CONDENSED CONSOLIDATED INCOME STATEMENTS - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]  
Net Sales$ 191.7$ 197.4
Cost of products sold87.290.8
Gross Profit104.5106.6
Research and development7.97.8
Selling and general expenses92.790.1
Other expense, net1.30.1
Operating Income2.68.6
Interest income0.50.0
Interest expense(3.5)(1.3)
(Loss) Income Before Income Taxes(0.4)7.3
Income tax provision(0.1)(1.9)
Net (Loss) Income$ (0.5)$ 5.4
(Loss) Earnings Per Share  
Basic (in dollars per share)$ (0.01)$ 0.11
Diluted (in dollars per share)$ (0.01)$ 0.11

AVNS Balance Sheet

2023-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents$ 95.7$ 127.7
Accounts receivable, net of allowances142.7167.9
Inventories200.0190.3
Prepaid and other current assets15.413.9
Total Current Assets453.8499.8
Property, Plant and Equipment, net163.5163.9
Operating Lease Right-of-Use Assets28.330.6
Goodwill821.5819.4
Other Intangible Assets, net244.7251.0
Deferred Tax Assets4.54.6
Other Assets18.617.6
TOTAL ASSETS1,734.91,786.9
Current Liabilities  
Current portion of long-term debt6.26.2
Current portion of operating lease liabilities12.112.8
Trade accounts payable59.667.9
Accrued expenses80.698.9
Total Current Liabilities158.5185.8
Long-Term Debt204.7226.3
Operating Lease Liabilities32.434.7
Deferred Tax Liabilities25.125.4
Other Long-Term Liabilities15.523.5
Total Liabilities436.2495.7
Commitments and Contingencies
Stockholders’ Equity  
Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued0.00.0
Common stock - $0.01 par value - authorized 300,000,000 shares, 46,660,199 outstanding as of March 31, 2023 and 46,528,907 outstanding as of December 31, 20220.50.5
Additional paid-in capital1,651.01,646.4
Accumulated deficit(253.6)(253.1)
Treasury stock(67.9)(66.8)
Accumulated other comprehensive loss(31.3)(35.8)
Total Stockholders’ Equity1,298.71,291.2
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 1,734.9$ 1,786.9